AQEAX
Price
$16.25
Change
-$0.01 (-0.06%)
Updated
Jun 2 closing price
Net Assets
5.2B
VFIAX
Price
$703.50
Change
+$0.93 (+0.13%)
Updated
Jun 2 closing price
Net Assets
1.6T
Interact to see
Advertisement

AQEAX vs VFIAX

Header iconAQEAX vs VFIAX Comparison
Open Charts AQEAX vs VFIAXBanner chart's image
AQEAX vs VFIAX Comparison Chart in %
View a ticker or compare two or three
VS
AQEAX vs. VFIAX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AQEAX is a Hold and VFIAX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VFIAX has more cash in the bank: 1.6T vs. AQEAX (5.2B). VFIAX pays higher dividends than AQEAX: VFIAX (1.02) vs AQEAX (0.47). AQEAX was incepted earlier than VFIAX: AQEAX (23 years) vs VFIAX (26 years). AQEAX (0.94) is less costly to investors than VFIAX (0.04). AQEAX is a more actively managed with annual turnover of: 49.00 vs. VFIAX (2.00). AQEAX has a lower initial minimum investment than VFIAX: AQEAX (2000) vs VFIAX (3000). VFIAX annual gain was more profitable for investors over the last year : 28.07 vs. AQEAX (12.71). VFIAX return over 5 years is better than : 81.36 vs. AQEAX (13.39).
AQEAXVFIAXAQEAX / VFIAX
Total Expense Ratio0.940.042,350%
Annual Report Gross Expense Ratio0.940.042,350%
Fund Existence23 years26 years-
Gain YTD7.82511.20470%
Front Load6%N/A-
Min. Initial Investment2000300067%
Min. Initial Investment IRAN/AN/A-
Net Assets5.2B1.6T0%
Annual Yield % from dividends0.471.0247%
Returns for 1 year12.7128.0745%
Returns for 3 years36.3577.5847%
Returns for 5 years13.3981.3616%
Returns for 10 years76.40262.1029%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLS472.4045.85
+10.75%
Celestica
EMBC3.470.18
+5.62%
Embecta Corp
MOGU2.180.08
+3.81%
MOGU
MRP27.830.10
+0.36%
Millrose Properties Inc
CGEM15.34-0.87
-5.37%
Cullinan Therapeutics